WO2005027015A2 - Method and system for quantitatively analyzing biological samples - Google Patents
Method and system for quantitatively analyzing biological samples Download PDFInfo
- Publication number
- WO2005027015A2 WO2005027015A2 PCT/US2004/029766 US2004029766W WO2005027015A2 WO 2005027015 A2 WO2005027015 A2 WO 2005027015A2 US 2004029766 W US2004029766 W US 2004029766W WO 2005027015 A2 WO2005027015 A2 WO 2005027015A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- automatically
- interest
- areas
- digital images
- analysis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 239000012472 biological sample Substances 0.000 title description 26
- 238000004458 analytical method Methods 0.000 claims abstract description 57
- 230000002055 immunohistochemical effect Effects 0.000 claims abstract description 23
- 239000012128 staining reagent Substances 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 32
- 238000003745 diagnosis Methods 0.000 claims description 27
- 238000012545 processing Methods 0.000 claims description 25
- 238000010827 pathological analysis Methods 0.000 claims description 16
- 108010077544 Chromatin Proteins 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 210000003483 chromatin Anatomy 0.000 claims description 6
- 238000011496 digital image analysis Methods 0.000 claims description 6
- 230000000877 morphologic effect Effects 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000000394 mitotic effect Effects 0.000 claims description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 3
- 238000007781 pre-processing Methods 0.000 claims 2
- 238000010586 diagram Methods 0.000 description 18
- 230000015654 memory Effects 0.000 description 16
- 238000004891 communication Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 9
- 239000013060 biological fluid Substances 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000011344 liquid material Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101150012579 ADSL gene Proteins 0.000 description 3
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 3
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000002952 image-based readout Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- -1 Ki-67 Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/10—Segmentation; Edge detection
- G06T7/11—Region-based segmentation
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/40—Analysis of texture
- G06T7/41—Analysis of texture based on statistical description of texture
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V10/00—Arrangements for image or video recognition or understanding
- G06V10/40—Extraction of image or video features
- G06V10/46—Descriptors for shape, contour or point-related descriptors, e.g. scale invariant feature transform [SIFT] or bags of words [BoW]; Salient regional features
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
- G06V20/695—Preprocessing, e.g. image segmentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2200/00—Indexing scheme for image data processing or generation, in general
- G06T2200/24—Indexing scheme for image data processing or generation, in general involving graphical user interfaces [GUIs]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10056—Microscopic image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30072—Microarray; Biochip, DNA array; Well plate
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/92—Computer assisted medical diagnostics
- Y10S128/922—Computer assisted medical diagnostics including image analysis
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Multimedia (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Probability & Statistics with Applications (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Quality & Reliability (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A method and system analyzing tissue or cell samples stored on laboratory slides or other media to identify properties of medical predictive and diagnostic relevance. The method and system includes automatically analyzing plural digital images created from plural biological tissue samples to which a staining reagent or a an immunohistochemical (IHC) compound has been applied, automatically quantitatively analyzing the relevant properties of the digital images, and creating interpretive data, images and reports resulting from such analysis.
Description
Title: METHOD AND SYSTEM FOR QUANTITATIVELY ANALYZING BIOLOGICAL SAMPLES
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This patent application claims priority to U.S. Provisional Patent
Application No. 60/501,142, filed September 10, 2003, and U.S. Provisional Patent Application No. 60/515,582 filed October 30, 2003, the contents of both of which are incorporated by reference.
FIELD OF THE INVENTION
[0002] This invention is related to analysis of laboratory data. More specifically, it relates to a method and system for quantitatively analyzing biological samples.
BACKGROUND OF THE INVENTION
[0003] Molecular methods are one standard approach used to diagnose and treat a number of diseases. Microarray based (e.g., High Content Screening (HCS)) analysis High Throughput Screening (HTS) analysis and gene expression profiling studies can be used to identify diagnosis markers, analyze disease progression and aid prognosis in developing cures (e.g., cancer progression and tumor analysis). This results in the availability of new and improved diagnostic tests to patients and physicians.
[0004] Such molecular analysis also provides the beginning of personalized medicine. Molecular-based therapies are becoming more targeted, such that knowledge of specific genetic variations present in individual patients guides selection of the best possible therapy, while minimizing chances of adverse reactions. This concept has also found its way to the drug development process, which is likely to result in an increasing number of new therapeutic agents that are prescribed in conjunction with "theranostic" genetic tests that guide use of the therapy in appropriate patient populations.
[0005] Gene expression using microarray technology allows the simultaneous assessment of the transcription of tens of thousands of genes, and of their relative expression between normal cells and malignant cells. Tissue Microarray Analysis (TMA) significantly impacts a researcher's ability to explore the genetic changes associated with cancer etiology and development and ultimately lead to the discovery of new biomarkers for disease diagnosis, prognosis and new therapeutic tools. Such onco- analysis at molecular level is much more specific and accurate than in the past.
[0006] Also the microarray genetic profile of patients can reveal individual patients response to chemotherapy. Comparative genome hybridization studies based on microarray technology may also predict alterations in cancer patients' genetic profiles. Microarray based expression-profiling studies and its correlation to clinical/histopathological/cystopathological findings still needs to be greatly fine-tuned to increase its significance. More sophisticated and high throughput validation approaches are required to allow the screening of hundreds of potential biomarkers onto thousands of tumor samples.
[0007] The use of newer imaging tools such as automated microscopes and digital imaging in the laboratory setting has resulted in a need for more sophisticated diagnostic software tools. Currently histological, cytological and imunohistochemical specimens are stored on glass slides, and these slides are read manually by technicians. Such analysis is, necessarily, based on subjective, human interpretation and is subject to human error. Clinicians and oncologists desire higher level of precision, objectivity, reproducibility and standardization in the pathological results.
[0008] Analyzing the tissue samples stained with immunohistochemical (IHC) reagents has been the key development in the practice of pathology. Both normal and diseased cells have certain physical characteristics that can be used to differentiate them. These characteristics include complex patterns, rare events, and subtle variations in color and intensity. These variants are what a pathologist looks for when scanning a slide with a manual microscope.
[0009] Hematoxillin and Eosin H&E) is a method of staining is used to study the morphology of tissue samples. Oncologists attempt to identify particular types of cancer by detecting variations in the patterns from the normal tissue. H & E staining can also be used to determine the pathological grading/ staging of cancer (e.g., the Richardson and Bloom Method).
[0010] This pathological grading of cancer is important from both a diagnostic and predictive perspective. Currently, pathologists must rely on manually analyzed samples without the benefit of any software tool. It is desirable to provide automated objective and reproducible results with fewer variations from pathologist-pathologist and lab-to-lab.
[0011] Until recently, most computer-driven systems could match the human eye in its ability to recognize complex patterns. There are limits, however, to the power of the human eye. Fatigue, repetitiveness of the task, large numbers of cells inside a given sample can be a problem for pathologists, as can the inability to distinguish between similar colors. Also computers typically can surpass the human eye in their ability to detect rare events and recognize subtle variations in color and intensity. Computer scientists first approached the challenge of automating the reading of samples on glass slides from a pattern-recognition angle, attempting to write a software program to duplicate the actions of the human brain.
[0012] Looking for a single object within a range of objects of similar but different sizes and orientations is very difficult. Additionally, to find the object when it is partially obscured or broken further increases the complexity. If a human looks at the same scene for approximately 5 to 10 minutes the brain acclimatizes to it and loses the ability to detect subtle changes in the scene. It is as though the observer is seeing a memory, and not the actual scene. Having a person spend a long period of time scanning slides that have similar features leads to fatigue and increases the chance of missing important information in the slides. Computers do not experience this fatigue and so are effective at detecting subtle changes in specific criteria. Therefore, rare-event detection is an appropriate use of a computer's power.
[0013] Additionally, because the human brain calculates brightness and color by comparison with the local context, a level of subjectivity is incorporated into reading stained slides manually. Thus, LHC/ H&E slides read by manual microscopy are scored only semi quantitatively, in accordance with the subjective and approximate nature of the human eye's color perception.
[0014] Based on the foregoing considerations, there is a need for reliable, information driven histopathological and cystopathological image analysis software system for quantification, image management and retrieval based on a self-learning framework using color, intensity, morphological patterns, artificial intelligence and expert system, personalization and remote communications.
[0015] Thus, it is desirable to provide a reliable, information driven software system for analyzing tissue and cell samples, which can create, retrieve, manage, and statistically and/or quantitatively analyze such images to increase their diagnostic and predictive value.
SUMMARY OF THE INVENTION
[0016] In accordance with preferred embodiments of the invention, some of the problems associated with human interpretation and error associated with manually analyzing images created from biological samples are overcome. A method and system for quantitatively analyzing images created from biological samples is presented.
[0017] The method and system includes, but is not limited to, automatically analyzing plural digital images created from plural biological tissue samples to which a staining reagent or a an immunohistochemical (IHC) compound has been applied, automatically quantitatively analyzing the relevant properties of the digital images, and creating interpretive data, images and reports resulting from such analysis.
[0018] The foregoing and other features and advantages of preferred embodiments of the present invention will be more readily apparent from the following detailed description. The detailed description proceeds with references to the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Preferred embodiments of the present invention are described with reference to the following drawings, wherein:
[0020] FIG. 1 is a block diagram illustrating an exemplary biological sample analysis processing system;
[0021] FIG. 2 is a block diagram illustrating applications of the biological sample analysis processing system of FIG. 1;
[0022] FIG. 3 is a flow diagram illustrating a method for automatically creating a medical diagnosis;
[0023] FIG. 4 is a block diagram illustrating a data flow for the method of FIG.
3;
[0024] FIG. 5 is a flow diagram illustrating a method for automatically creating a medical diagnosis;
[0025] FIG. 6 is a block diagram illustrating a data flow for the method of FIG.
4;
[0026] FIG. 7 is a flow diagram illustrating a method completing a pathological diagnosis with a pathiam; and
[0027] FIG. 8 is a block diagram illustrating another data flow for analyzing digital images.
DETAILED DESCRIPTION OF THE INVENTION
Exemplary biological sample analysis system
[0028] FIG. 1 is a block diagram illustrating an exemplary biological sample analysis processing system 10. The exemplary biological sample analysis processing system 10 includes, but is not limited to, one or more computers 12 with a computer display 14. The computer display 14 presents a windowed graphical user interface (GUI) 16 with multiple windows to a user. The one or more computers 12 may be replaced with client terminals in communications with one or more servers, a personal digital/data assistant (PDA), a laptop computer, a mobile computer, an Internet appliance, one or two-way pagers, or other similar mobile or hand-held electronic device.
[0029] The one or more computers are associated with one or more databases 18
(one of which is illustrated) includes biological sample information in various digital image or digital data formats. The one or more databases 18 may be integral to a memory system on the computer 12 or in secondary storage such as a hard disk, floppy disk, optical disk, or other non-volatile mass storage devices. The computer 12 includes one or more applications 20 for analyzing biological samples.
[0030] The one or more computers 12 are also in communications with a communications network 22 such as the Internet, an intranet, a Local Area Network (LAN) or other computer network. Functionality of the medical data analyzing system 10 can also be distributed over plural computers 12 via the communications network 22.
[0031] The communications network 22 includes, but is not limited to, the
Internet, an intranet, a wired Local Area Network (LAN), a wireless LAN (WiLAN), a Wide Area Network (WAN), a Metropolitan Area Network (MAN), Public Switched Telephone Network (PSTN) and other types of communications networks 18 providing voice, video and data communications.
[0032] The communications network 22 may include one or more gateways, routers, or bridges. As is known in the art, a gateway connects computer networks using different network protocols and/or operating at different transmission capacities. A router receives transmitted messages and forwards them to their correct destinations
over the most efficient available route. A bridge is a device that connects networks using the same communications protocols so that information can be passed from one network device to another.
[0033] The commumcations network 22 may include one or more servers and one or more web-sites accessible by user to send and receive information useable by the one or more computers 12. The communications network 22 includes, but is not limited to data networks using the Transmission Control Protocol (TCP), User Datagram Protocol (UDP), Internet Protocol (IP ) and other data protocols.
[0034] As is know in the art, TCP provides a connection-oriented, end-to-end reliable protocol designed to fit into a layered hierarchy of protocols which support multi-network applications. TCP provides for reliable inter-process communication between pairs of processes in network devices attached to distinct but interconnected networks. For more information on TCP see Internet Engineering Task Force (ITEF) Request For Comments (RFC)-793, the contents of which are incorporated herein by reference.
[0035] As is know in the art, UDP provides a connectionless mode of communications with datagrams in an interconnected set of computer networks. UDP provides a transaction oriented datagram protocol, where delivery and duplicate packet protection are not guaranteed. For more information on UDP see IETF RFC-768, the contents of which incorporated herein by reference.
[0036] As is known in the art, IP is an addressing protocol designed to route traffic within a network or between networks. TJP is described in IETF Request For Comments (RFC)-791, the contents of which are incorporated herein by reference. However, more fewer or other protocols can also be used on the communications network 28 and the present invention is not limited to TCP/UDP/IP.
[0037] The communications network 22 may also include portions of a Public
Switched Telephone Network (PSTN) or cable television network (CATV) that connects the one or more computers 12 via one or more twisted pairs of copper wires, coaxial cable, fiber optic cable, other connection media or other connection interfaces with corresponding wired connection protocols (e.g., DSL, ADSL, ISDN, etc.) The PSTN is any public switched telephone network provided by AT&T, GTE, Sprint, MCI, SBC, Verizon and others.
[0038] Preferred embodiments of the present invention includes network devices and interfaces that are compliant with all or part of standards proposed by the Institute of Electrical and Electronic Engineers (IEEE), International Telecommunications Union-Telecommunication Standardization Sector (ITU), European Telecommunications Standards Institute (ETSI), Internet Engineering Task Force (IETF), U.S. National Institute of Security Technology (NIST), American National Standard Institute (ANSI), Wireless Application Protocol (WAP) Forum, Data Over Cable Service Interface Specification (DOCSIS) Forum, Bluetooth Forum, or the ADSL Forum. However, network devices and interfaces based on other standards could also be used.
[0039] IEEE standards can be found on the World Wide Web at the Universal
Resource Locator (URL) "www.ieee.org." The ITU, (formerly known as the CCITT) standards can be found at the URL "www.itu.ch." ETSI standards can be found at the URL "www.etsi.org." IETF standards can be found at the URL "www.ietf.org." The NIST standards can be found at the URL "www.nist.gov." The ANSI standards can be found at the URL "www.ansi.org." The DOCSIS standard can be found at the URL "www.cablemodem.com." Bluetooth Forum documents can be found at the URL "www.bluetooth.com." WAP Forum documents can be found at the URL "www.wapforum.org." ADSL Forum documents can be found at the URL "www.adsl.com."
[0040] The digital images include digital images of biological samples taken via a microscope with a digital camera and stored in a variety of digital image formats including, bit-mapped, joint pictures expert group (JPEG), graphics interchange format (GIF), etc. However, the present invention is not limited to these digital image formats and other digital image or digital data formats can also be used to practice the invention.
[0041] The digital images are typically obtained by magnifying the biological samples with a microscope or other magnifying device and capturing a digital image of the magnified biological sample (e.g., groupings of plural magnified cells, etc.).
[0042] One embodiment includes a microscope or other magnifying device and a digital or analog camera. Another embodiment optionally includes a microscope with a digital camera 24.
[0043] The term "sample" includes cellular material derived from a biological organism. Such samples include but are not limited to hair, skin samples, tissue samples,
cultured cells, cultured cell media, and biological fluids. The term "tissue" refers to a mass of connected cells (e.g., CNS tissue, neural tissue, or eye tissue) derived from a human or other animal and includes the connecting material and the liquid material in association with the cells. The term "biological fluid" refers to liquid material derived from a human or other animal. Such biological fluids include, but are not limited to, blood, plasma, serum, serum derivatives, bile, phlegm, saliva, sweat, amniotic fluid, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF. The term "sample" also includes media containing isolated cells. The quantity of sample required to obtain a reaction may be determined by one skilled in the art by standard laboratory techniques. The optimal quantity of sample may be determined by serial dilution.
[0044] An operating environment for the devices biological sample analysis processing system 10 include a processing system with one or more high speed Central Processing Unit(s) ("CPU"), processors and one or more memories. In accordance with the practices of persons skilled in the art of computer programming, the present invention is described below with reference to acts and symbolic representations of operations or instructions that are performed by the processing system, unless indicated otherwise. Such acts and operations or instructions are referred to as being "computer-executed," "CPU-executed," or "processor-executed."
[0045] It will be appreciated that acts and symbolically represented operations or instructions include the manipulation of electrical signals or biological signals by the CPU or processor. An electrical system or biological system represents data bits which cause a resulting transformation or reduction of the electrical signals or biological signals, and the maintenance of data bits at memory locations in a memory system to thereby reconfigure or otherwise alter the CPU's or processor's operation, as well as other processing of signals. The memory locations where data bits are maintained are physical locations that have particular electrical, magnetic, optical, or organic properties corresponding to the data bits.
[0046] The data bits may also be maintained on a computer readable medium including magnetic disks, optical disks, organic memory, and any other volatile (e.g., Random Access Memory ("RAM")) or non-volatile (e.g., Read-Only Memory ("ROM"), flash memory, etc.) mass storage system readable by the CPU. The computer readable medium includes cooperating or interconnected computer readable medium, which exist exclusively on the processing system or can be distributed among multiple interconnected processing systems that may be local or remote to the processing system.
[0047] The digital images include digital images of biological samples taken with a camera such as a digital camera and stored in a variety of digital image formats including, bit-mapped, joint pictures expert group (JPEG), graphics interchange format (GIF), etc. However, the present invention is not limited to these digital image formats and other digital image or digital data formats can also be used to practice the invention.
[0048] The digital images are typically obtained by magnifying the biological samples with a microscope or other magnifying device and capturing a digital image of the magnified biological sample (e.g., groupings of plural magnified cells, etc.).
[0049] The term "sample" includes cellular material derived from a biological organism. Such samples include but are not limited to hair, skin samples, tissue samples, cultured cells, cultured cell media, and biological fluids. The term "tissue" refers to a mass of connected cells (e.g., CNS tissue, neural tissue, or eye tissue) derived from a human or other animal and includes the connecting material and the liquid material in association with the cells. The term "biological fluid" refers to liquid material derived from a human or other animal. Such biological fluids include, but are not limited to, blood, plasma, serum, serum derivatives, bile, phlegm, saliva, sweat, amniotic fluid, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF. The term "sample" also includes media containing isolated cells. The quantity of sample required to obtain a reaction may be determined by one skilled in the art by standard laboratory techniques. The optimal quantity of sample may be determined by serial dilution.
[0050] An operating environment for the devices biological sample analysis processing system 10 include a processing system with one or more high speed Central Processing Unit(s) ("CPU"), processors and one or more memories. In accordance with the practices of persons skilled in the art of computer programming, the present invention is described below with reference to acts and symbolic representations of operations or instructions that are performed by the processing system, unless indicated otherwise. Such acts and operations or instructions are referred to as being "computer-executed," "CPU-executed," or "processor-executed."
[0051] It will be appreciated that acts and symbolically represented operations or instructions include the manipulation of electrical signals or biological signals by the CPU or processor. An electrical system or biological system represents data bits which cause a resulting transformation or reduction of the electrical signals or biological signals, and the maintenance of data bits at memory locations in a memory system to thereby reconfigure or otherwise alter the CPU's or processor's operation, as well as
other processing of signals. The memory locations where data bits are maintained are physical locations that have particular electrical, magnetic, optical, or organic properties corresponding to the data bits.
[0052] The data bits may also be maintained on a computer readable medium including magnetic disks, optical disks, organic memory, and any other volatile (e.g., Random Access Memory ("RAM")) or non- volatile (e.g., Read-Only Memory ("ROM"), flash memory, etc.) mass storage system readable by the CPU. The computer readable medium includes cooperating or interconnected computer readable medium, which exist exclusively on the processing system or can be distributed among multiple interconnected processing systems that may be local or remote to the processing system.
Analyzing biological samples to create a medical diagnosis
[0053] FIG. 2 is a block diagram 26 illustrating applications 20 of the biological sample analysis processing system 10, that include, but are not limited to a digital image analysis module 28 for automatically analyzing a plural digital images created from a plural biological tissue samples to which an staining reagent has been applied to determine one or more areas of interest and for automatically analyzing a plural digital images created from a plural biological tissues samples to which an immunohistochemical (1HC) compound has been applied to determine one or more areas of interest, a medical analysis module 30 for automatically quantitatively analyzing the one or more determined areas of interest to automatically generate additional interpretive images, medical data, medical statistics or medical reports of predictive value or diagnostic value, a display module 32 to display the plural digital images, the additional interpretive images, the medical data, medical statistics or medical reports on a graphical user interface display, a recorder module 34 to automatically record, store and apply knowledge generated by the quantitatively analysis of the one or more determined areas of interest.
[0054] hi one embodiment the applications 20 are software applications.
However the invention is not limited
[0055] FIG. 3 is a flow diagram illustrating a Method 36 for automatically creating a medical diagnosis. At Step 38, plural digital images created from plural biological tissue samples to which a staining reagent has been applied are acquired. At Step 40, the plural digital images are pre-processed to adjust, if necessary, a contrast level and a color level. At Step 42, a histogram analysis is performed on the plural
digital images using grey and red, green, blue (RGB) luminosity values to locate one or more areas of interest. At Step 44, one or more areas of interest in which one or more human cancer cells may be present are determined using automatic chromatin pattern analysis, automatic nucleoar pattern analysis or automatic mitotic activity pattern analysis. At Step 46, the determined one or more areas of interest in which one or more human cancer cells may be present are classified and used to create a medical diagnosis.
[0056] In one embodiment, Method 36 further comprises creating new medical knowledge using the determined one or more areas of interest and automatically adjusting the processing completed at Steps 40-46 to further refine the ability to automatically detect and classify one or more human cancer cells to create a medical diagnosis.
[0057] FIG. 4 is a block diagram 48 illustrating a data flow for Method 36. FIG.
4 illustrates as analysis of digital images are completed new medical diagnostic knowledge is obtained. The new medical diagnostic knowledge is then automatically re-applied to the analysis techniques used to further the further refine the ability to automatically detect and classify one or more cancer cells to create a medical diagnosis.
[0058] FIG. 5 is a flow diagram illustrating a Mpthod 50 for automatically creating a medical diagnosis. At Step 52, plural digital images created from plural biological tissue samples to which an immunohistochemical (LHC) compound has been applied are acquired. At Step 54, the plural digital images are pre-processed to adjust, if necessary, a contrast level and a color level. At Step 56, a histogram analysis is performed on the plural digital images using grey and red, green, blue (RGB) luminosity values to locate one or more areas of interest. At Step 58, one or more areas of interest in which one or more cancer cells may be present are determined using automatic nuclear pattern analysis, automatic cytoplasmic pattern analysis or automatic membrane pattern analysis. At Step 60, the determined one or more areas of interest in which one or more cancer cells may be present are classified and used to create a medical diagnosis.
[0059] In one embodiment, Method 50 further comprises creating new medical knowledge using the determined one or more areas of interest and automatically adjusting the processing completed at Steps 52-60 to further refine the ability to automatically detect and classify one or more, cancer cells to create a medical diagnosis.
[0060] FIG. 6 is a block diagram 62 illustrating a data flow for Method 50. FIG.
5 illustrates as analysis of digital images are completed new medical diagnostic knowledge is obtained. The new medical diagnostic knowledge is then automatically re-applied to the analysis techniques used to further the further refine the ability to automatically detect and classify one or more cancer cells to create a medical diagnosis.
[0061] A PATHIAM is a tool used by pathologists to assist in quantification and reporting a pathological diagnosis. A PATHIAM automatically uses digital image intensity values and classifies them into useable identifiable patterns to locate biological components such as cell membranes and other shapes decoded as morphological feature patterns and other types of patterns. A PATHIAM is thus used an aid or enabling tool for pathologists and other medical or research professionals to help them in analyzing biological tissue and other biological samples with more precision and accuracy using automated processes.
[0062] FIG. 7 is a flow diagram illustrating a Method for 64 completing a pathological diagnosis with a pathiam. At Step 66, plural digital image intensity values from a plural digital images created from plural biological tissue samples to which a staining reagent or an immunohistochemical (IHC) compound has been applied are automatically analyzed to determine one or more areas of interest. At Step 68, the determined one or more areas of interest are automatically classified into one or more patterns used to locate one or more morphological features from the biological tissue samples in which one or more human cancer cells may be present. At Step 70, a pathological diagnosis is automatically created using the classified one or more patterns.
[0063] FIG. 8 is a block diagram 72 illustrating another data flow for analyzing digital images. The applications 20 are capable of acquiring images from digital microscopic equipment or from image databases, either managed or unmanaged.
[0064] In one embodiment, the applications 20 are based on an expert system framework for analyzing Histopathological and Cytopathological biopsy slides, which may be stained with, for example, Hematoxillin-Eosin or with Imunohistochemical reagents. The stained slides can then subjected to microscopic examinations.
[0065] The parameters used for digital image analysis are configurable by a user and default parameters may be modified and refined per set of images processed via self-learning engine collecting knowledge across the framework.
[0066] The analyzed digital images also are grouped / clustered / classified based on similar trends and features and each formed cluster can then aid the knowledge extraction step indicated by a possible knowledge base (KB) creation. The KB creation collects information thus received as a part of analysis, which it may correlate to the statistical libraries and other database to generate knowledge rules.
[0067] The system includes but is not limited to the steps of creating or capturing images of the cell or tissue or other biological samples. The. biological samples may, but are not required to be, treated with chemical reagents to stain or enhance the visibility of certain properties of the biological samples.
[0068] The properties of the captured images are quantitatively analyzed by the software to generate additional interpretive images, data and/or reports of predictive and diagnostic value having various content, appearance and format.
[0069] Exemplary applications of the invention may include but are not limited to: (1) Oncopathology Diagnosis: a PATHIAM may be useful in Oncopathological or other diagnosis of biopsy slides. For example, digital images of H&E and IHC stained breast biopsy slides can be analyzed using PATHIAM for pathological TNM scoring and common IHC breast panel analysis such as ER, PR, HER-2 positivity tests. These analysis results may be useful not only from diagnostic viewpoint but may have prognostic value associated with it; (2) Oncopathology Research: an immunostain database data with statistical values and tissue microarray features are useful to research community characteristics. For example, a PATHIAM may help the pathologist choose the best panel of immunostains, which may in turn help differentiate between the tumors. This may be a useful application considering the market availability of a large pool of antibody reagents. The knowledge database lists the antibodies that can differentiate between the type of tumors entered by the user (e.g., ductal ca vs. lobular ca ). The system may also grade antibodies with respect to their ability to differentiate between the tumors; (3) Cytopathogocial Diagnosis: high power image analysis of H&E stained slides is beneficial for the cytopathologists. Nuclear grading based on nuclear pleomorphism with graphical display 14 and quantitification of chromatin and nucleolar pattern may be of significance in cystopatho logical diagnosis of surgical/FNA slides. This assists in distinguishing benign and malignant tumorsl (4) Cytopathogocial Research: comparison of graphs and values of nuclear pleomorphism, chromatin and nucleolar pattern with prior cases having similar or closely similar results may assist cytopathology researchers; (5) Histotopathological Diagnosis: A PATHIAM is useful for histopathological or other diagnosis of surgical biopsy slides. The H&E module may
help in morphological analysis while IHC marker may be useful for standardization and quantification of biomarker levels on tissue samples. The peer review model is also useful from a histopathological or other diagnostic point of view; (6) Histopathogocial Research: useful features for histopathical research may include image management and retrieval and peer review; (7) Molecular Diagnostics: The system includes functional capabilities such as object identification, object counting, staining-intensity measurement, and morphometric characterization. The functions are applied individually or in combinations to enable licensed laboratory professionals or others to analyze any slides and other media stained with H&E, IHC or ICC reagents, such as those stained for ER/PR, HER2, EGFR, Ki-67, p53, and other stains. PATHIAM will also assist Microarray based expression profiling studies and its correlation to clinical/ histopathological/ cytopathological findings, which is the basis of molecular diagnostics. This potentially may allow the screening of hundreds of potential biomarkers onto thousands of tumor or other samples simultaneously; (8) Pharmacogenomics, Drug Discovery, and Clinical Trials: It is anticipated that growth in the field and emergence of advanced bio-informatics tools for data mining and analysis with simpler array designs may facilitate this technology in diagnosis and prognosis of cancers. And very soon the screening tests based on microarray findings may one of the many tests performed on cancer patients in a multidisciplinary team patient management approach to cancer diagnosis and prognosis.
[0070] It should be understood that the programs, processes, methods and system described herein are not related or limited to any particular type of computer or network system (hardware or software), unless indicated otherwise. Various combinations of general purpose, specialized or equivalent computer components including hardware, software, and firmware and combinations thereof may be used with or perform operations in accordance with the teachings described herein.
[0071] In view of the wide variety of embodiments to which the principles of the present invention can be applied, it should be understood that the illustrated embodiments are exemplary only, and should not be taken as limiting the scope of the present invention. For example, the steps of the flow diagrams may be taken in sequences other than those described, and more fewer or equivalent elements may be used in the block diagrams.
[0072] The claims should not be read as limited to the described order or elements unless stated to that effect. In addition, use of the term "means" in any claim is
intended to invoke 35 U.S.C. §112, paragraph 6, and any claim without the word "means" is not so intended.
[0073] Therefore, all embodiments that come within the scope and spirit of the following claims and equivalents thereto are claimed as the invention.
Claims
1. A pathological analysis system, comprising in combination: a digital image analysis module for automatically analyzing a plurality of digital images created from a plurality of biological tissue samples to which an staining reagent has been applied to determine one or more areas of interest and for automatically analyzing a plurality of digital images created from a plurality of biological tissues samples to which an immunohistochemical compound has been applied to determine one or more areas of interest; an medical analysis module for automatically quantitatively analyzing the one or more determined areas of interest to automatically generate additional interpretive images, medical data, medial statistics or medical reports of predictive value or diagnostic value; a display module to display the plurality of digital images, the additional interpretive images, the medical data, medical statistics or medical reports on a graphical user interface display; and a recorder module to automatically record, store and apply knowledge generated by the quantitatively analysis of the one or more determined areas of interest.
2. The pathological analysis of Claim 1 in which the digital image analysis module automatically analyzes a plurality of digital images which an staining reagent has been applied to determine one or more areas of interest in which one or more human cancer cells may be present.
3. The pathological analysis system of Claim 1 in which the digital image analysis module includes automatically analyzing a plurality of digital images to which a staining reagent has been applied to determine one or more areas of interest in which one or more human cancer cells may be present using automatic chromatin pattern analysis, automatic nucleoar pattern analysis or automatic mitotic activity pattern analysis.
4. The pathological analysis system of Claim 1 in which the digital image analysis module includes automatically analyzing a plurality of digital images created from a plurality of biological tissues samples to which an immunohistochemical (IHC) compound has been applied to determine one or more areas of interest in which one or more human cancer cells may be present using automatic nuclear pattern analysis, automatic cytoplasmic pattern analysis or automatic membrane pattern analysis.
5. The pathological analysis system of Claim 1 further comprising: a microscope; and a digital camera.
6. A pathological analysis system, comprising in combination: a means for automatically analyzing a plurality of digital images created from a plurality of biological tissue samples to which an staining reagent has been applied to determine one or more areas of interest and for automatically analyzing a plurality of digital images created from a plurality of biological tissues samples to which an immunohistochemical compound has been applied to determine one or more areas of
interest; a means for automatically quantitatively analyzing the one or more determined areas of interest to automatically generate additional interpretive images, medical data, medial statistics or medical reports of predictive value or diagnostic value; a means for displaying the plurality of digital images, the additional interpretive images, the medical data, medical statistics or medical reports on a graphical user interface display; and a means for automatically recording, storing and applying knowledge generated by the quantitatively analysis of the one or more determined areas of interest.
7. The pathological analysis of Claim 6 in which the a means for automatically analyzing a plurality of digital images automatically analyzes a plurality of digital images which an staining reagent has been applied to determine one or more areas of interest in which one or more human cancer cells may be present.
8. The pathological analysis system of Claim 6 in which the means for automatically analyzing a plurality of digital images includes automatically analyzing a plurality of digital images to which a staining reagent has been applied to determine one or more areas of interest in which one or more human cancer cells may be present using automatic chromatin pattern analysis, automatic nucleoar pattern analysis or automatic mitotic activity pattern analysis.
9. The pathological analysis system of Claim 6 in which the means for automatically analyzing a plurality of digital images includes automatically analyzing a plurality of digital images created from a plurality of biological tissues samples to which an immunohistochemical (IHC) compound has been applied to determine one or more areas of interest in which one or more human cancer cells may be present using automatic nuclear nuclear pattern analysis, automatic cytoplasmic pattern analysis or automatic membrane pattern analysis.
10. The pathological analysis system of Claim 6 further comprising: a means for magnifying microscopic biological tissue samples; and a means for creating digital photographs.
11. A method for automatically creating a medical diagnosis, comprising: acquiring a plurality of digital images created from the plurality of biological tissue samples to which a staimng reagent has been applied; automatically pre-processing the plurality of digital images to adjust, if necessary, a contrast level and a color level; automatically performing a histogram analysis on the plurality of digital images using grey and red, green, blue (RGB) luminosity values to locate one or more areas of interest; automatically determining one or more areas of interest in which one or more cancer cells may be present using automatic chromatin pattern analysis, automatic nucleoar pattern analysis or automatic mitotic activity pattern analysis; and automatically classifying the determined one or more areas of interest in which one or more cancer cells may be present, thereby creating a medical diagnosis.
12. The method of Claim 11 further comprising a computer readable medium having stored therein instructions for causing a processor to execute the steps of the method.
13. The method of Claim 11 in which the staining reagent includes a Hematoxillin and Eosin (H&E) staining reagent.
14. The method of Claim 11 further comprising: creating new medical knowledge using the determined one or more areas of interest which one or more cancer cells may be present; and automatically adjusting the processing completed on the plurality of digital images to further refine the ability to automatically detect and classify one or more cancer cells to create a medical diagnosis.
15. A method for automatically creating a medical diagnosis, comprising: acquiring a plurality of digital images created from the plurality of biological tissue samples to which an immunohistochemical (THC) compound has been applied; automatically pre-processing the plurality of digital images to adjust, if necessary, a contrast level and a color level; automatically performing a histogram analysis on the plurality of digital images using grey and red, green, blue (RGB) luminosity values to locate one or more areas of interest; automatically determining one or more areas of interest in which one or more cancer cells may be present using automatic nuclear pattern analysis, automatic cytoplasmic pattern analysis or automatic membrane pattern analysis; and automatically classifying the determined one or more areas of interest in which one or more cancer cells may be present, thereby creating a medical diagnosis.
16. The method of Claim 15 further comprising a computer readable medium having stored therein instructions for causing a processor to execute the steps of the method.
17. The method of Claim 15 further comprising: creating new medical knowledge using the determined one or more areas of interest which one or more cancer cells may be present; and automatically adjusting the processing completed on the plurality of digital images to further refine the ability to automatically detect and classify one or more cancer cells to create a medical diagnosis.
18. A method for completing a pathological diagnosis with a pathiam,
comprising: automatically analyzing a plurality of digital image intensity values from a plurality of digital images created from a plurality of biological tissue samples to which a staining reagent or a an immunohistochemical (IHC) compound has been applied to determine one or more areas of interest; automatically classifying the determined one or more areas of interest into one or more patterns used to locate one or more morphological features from the biological tissue samples in which one or more human cancer cells may be present; automatically creating a pathological diagnosis using the classified one or more patterns.
19. The method of Claim 18 further comprising a computer readable medium having stored therein instructions for causing a processor to execute the steps of the method.
20. The method of Claim 18 staining reagent includes a Hematoxillin and Eosin (H&E) staining reagent.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50141203P | 2003-09-10 | 2003-09-10 | |
US60/501,412 | 2003-09-10 | ||
US51558203P | 2003-10-30 | 2003-10-30 | |
US60/515,582 | 2003-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005027015A2 true WO2005027015A2 (en) | 2005-03-24 |
WO2005027015A3 WO2005027015A3 (en) | 2005-06-16 |
Family
ID=34316479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/029766 WO2005027015A2 (en) | 2003-09-10 | 2004-09-10 | Method and system for quantitatively analyzing biological samples |
Country Status (2)
Country | Link |
---|---|
US (4) | US20050136509A1 (en) |
WO (1) | WO2005027015A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2485883A (en) * | 2010-11-26 | 2012-05-30 | Siemens Medical Solutions | Retrieval and reviewing of medical image processing |
US8417015B2 (en) | 2007-08-06 | 2013-04-09 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
US8655037B2 (en) | 2007-05-14 | 2014-02-18 | Historx, Inc. | Compartment segregation by pixel characterization using image data clustering |
WO2017051190A1 (en) * | 2015-09-23 | 2017-03-30 | Pathxl Limited | Method and apparatus for tissue recognition |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8719053B2 (en) | 2003-07-17 | 2014-05-06 | Ventana Medical Systems, Inc. | Laboratory instrumentation information management and control network |
US7860727B2 (en) | 2003-07-17 | 2010-12-28 | Ventana Medical Systems, Inc. | Laboratory instrumentation information management and control network |
US20080235055A1 (en) * | 2003-07-17 | 2008-09-25 | Scott Mattingly | Laboratory instrumentation information management and control network |
US8068988B2 (en) | 2003-09-08 | 2011-11-29 | Ventana Medical Systems, Inc. | Method for automated processing of digital images of tissue micro-arrays (TMA) |
US20050136509A1 (en) | 2003-09-10 | 2005-06-23 | Bioimagene, Inc. | Method and system for quantitatively analyzing biological samples |
CA2567293C (en) * | 2004-05-27 | 2017-05-16 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
US20070076929A1 (en) * | 2005-10-05 | 2007-04-05 | General Electric Company | System and method for automatic post processing image generation |
US8295562B2 (en) * | 2006-01-13 | 2012-10-23 | Carl Zeiss Microimaging Ais, Inc. | Medical image modification to simulate characteristics |
JP2009526519A (en) * | 2006-01-17 | 2009-07-23 | セルーメン、インコーポレイテッド | Methods for predicting biological system response |
FI20060331A0 (en) * | 2006-04-05 | 2006-04-05 | Kari Seppaelae | Method and device for shape measurement / shape identification |
WO2007136724A2 (en) | 2006-05-17 | 2007-11-29 | Cellumen, Inc. | Method for automated tissue analysis |
WO2008005426A2 (en) * | 2006-06-30 | 2008-01-10 | University Of South Florida | Computer-aided pathological diagnosis system |
WO2008060483A2 (en) * | 2006-11-10 | 2008-05-22 | Cellumen, Inc. | Protein-protein interaction biosensors and methods of use thereof |
ES2599902T3 (en) * | 2007-06-15 | 2017-02-06 | Novartis Ag | Microscope system and method to obtain standardized sample data |
WO2009020621A1 (en) * | 2007-08-07 | 2009-02-12 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
US7978258B2 (en) * | 2007-08-31 | 2011-07-12 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
WO2009044827A1 (en) * | 2007-10-05 | 2009-04-09 | Sharp Kabushiki Kaisha | Color adjustment circuit |
JP5365011B2 (en) * | 2008-01-29 | 2013-12-11 | 日本電気株式会社 | Pathological diagnosis support apparatus, pathological diagnosis support method, and program |
US8369600B2 (en) * | 2008-03-25 | 2013-02-05 | General Electric Company | Method and apparatus for detecting irregularities in tissue microarrays |
WO2010003044A2 (en) * | 2008-07-03 | 2010-01-07 | Nec Laboratories America, Inc. | Epithelial layer detector and related methods |
JP5315411B2 (en) * | 2008-07-03 | 2013-10-16 | エヌイーシー ラボラトリーズ アメリカ インク | Mitotic image detection device and counting system, and method for detecting and counting mitotic images |
US9240043B2 (en) * | 2008-09-16 | 2016-01-19 | Novartis Ag | Reproducible quantification of biomarker expression |
US20100111398A1 (en) * | 2008-10-31 | 2010-05-06 | Texas Instruments Incorporated | Method and system for detection of oral sub-mucous fibrosis using microscopic image analysis of oral biopsy samples |
US8861810B2 (en) * | 2009-01-06 | 2014-10-14 | Vala Sciences, Inc. | Automated image analysis with GUI management and control of a pipeline workflow |
CN102405414B (en) * | 2009-04-20 | 2015-09-23 | 株式会社日立高新技术 | Automatic analysing apparatus |
US8891851B2 (en) * | 2009-07-15 | 2014-11-18 | Glenn F. Spaulding | Home healthcare management system and hardware |
JP5348411B2 (en) * | 2009-07-15 | 2013-11-20 | 富士ゼロックス株式会社 | Image processing apparatus and image processing program |
JP5659158B2 (en) * | 2009-07-21 | 2015-01-28 | 国立大学法人京都大学 | Image processing apparatus, culture observation apparatus, and image processing method |
US20110122242A1 (en) * | 2009-10-26 | 2011-05-26 | Texas Instruments Incorporated | Digital microscopy equipment with image acquisition, image analysis and network communication |
AP3556A (en) | 2010-02-10 | 2016-01-18 | Kickstart International Inc | Human-powered irrigation pump |
CA2788664C (en) | 2010-03-04 | 2023-04-11 | Ventana Medical Systems, Inc. | Processing system for processing specimens using acoustic energy |
US10126216B2 (en) | 2011-02-17 | 2018-11-13 | Ventana Medical Systems, Inc. | Method for tissue sample fixation |
US10539487B2 (en) | 2010-03-04 | 2020-01-21 | Ventana Medical Systems, Inc. | Systems and methods for monitoring tissue sample processing |
US10621307B2 (en) * | 2010-04-29 | 2020-04-14 | Definiens Gmbh | Image-based patient profiles |
US20120207360A1 (en) * | 2011-02-11 | 2012-08-16 | Courosh Mehanian | Systems and Methods for Object Identification |
EP2686688B1 (en) | 2011-03-17 | 2019-05-08 | Cernostics, Inc. | Systems and compositions for diagnosing barrett's esophagus and methods of using the same |
WO2012142474A2 (en) | 2011-04-13 | 2012-10-18 | Thermolife International, Llc | N-acetyl beta alanine methods of use |
US9019367B2 (en) * | 2011-06-10 | 2015-04-28 | Wuerth Elektronik Ics Gmbh & Co. Kg | Method for dynamically detecting the fill level of a container, container therefor, and system for dynamically monitoring the fill level of a plurality of containers |
WO2012174535A1 (en) | 2011-06-17 | 2012-12-20 | Constitution Medical, Inc. | Solutions for histoprocessing of biological samples |
WO2013013117A1 (en) | 2011-07-20 | 2013-01-24 | Mikroscan Technologies, Inc. | Network-based pathology system with desktop slide scanner |
US8774518B2 (en) | 2011-08-02 | 2014-07-08 | Nec Laboratories America, Inc. | Digital pathology system with low-latency analytics |
US20140220598A1 (en) * | 2011-09-09 | 2014-08-07 | Tohoku University | Biological substance detection method |
CN103959332B (en) | 2011-11-17 | 2017-05-17 | 皇家飞利浦有限公司 | Image processing |
WO2013109802A1 (en) * | 2012-01-19 | 2013-07-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histology recognition to automatically score and quantify cancer grades and individual user digital whole histological imaging device |
EP2634723B1 (en) * | 2012-03-02 | 2019-08-21 | F. Hoffmann-La Roche AG | Determination of a terminal's position for displaying a gui element |
US9147104B2 (en) | 2012-11-05 | 2015-09-29 | The United States Of America As Represented By The Secretary Of The Air Force | Systems and methods for processing low contrast images |
WO2014145181A1 (en) | 2013-03-15 | 2014-09-18 | Morphotek, Inc. | Methods for determining prognosis of colorectal cancer |
US9946953B2 (en) * | 2013-05-10 | 2018-04-17 | Koninklijke Philips N.V. | Apparatus and method for processing images of tissue samples |
US20150030215A1 (en) * | 2013-07-26 | 2015-01-29 | Abbott Point Of Care, Inc. | Method and apparatus for producing an image of undiluted whole blood sample having wright stain coloration |
US9585627B2 (en) * | 2013-08-14 | 2017-03-07 | Siemens Healthcare Gmbh | Histological differentiation grade prediction of hepatocellular carcinoma in computed tomography images |
US10119901B2 (en) | 2013-11-15 | 2018-11-06 | Mikroscan Technologies, Inc. | Geological scanner |
US11093869B2 (en) | 2014-02-13 | 2021-08-17 | Brewmetrix Inc. | Analytical system with iterative method of analyzing data in web-based data processor with results display designed for non-experts |
US11232565B2 (en) * | 2014-04-03 | 2022-01-25 | Koninklijke Philips N.V. | Examining device for processing and analyzing an image |
WO2015168026A2 (en) * | 2014-04-28 | 2015-11-05 | The Broad Institute, Inc. | Method for label-free image cytometry |
JP6301199B2 (en) * | 2014-05-30 | 2018-03-28 | 富士フイルム株式会社 | Cell evaluation apparatus, method and program |
US10162166B2 (en) | 2014-10-28 | 2018-12-25 | Mikroscan Technologies, Inc. | Microdissection viewing system |
JP6908531B2 (en) | 2015-01-27 | 2021-07-28 | ベンタナ メディカル システムズ, インコーポレイテッド | Tissue sample fixation method using long-term immersion in an aldehyde-based fixation solution |
WO2016146616A1 (en) | 2015-03-16 | 2016-09-22 | Ventana Medical Systems, Inc. | Control slides for immunohistochemistry generated from three-dimensional cell line cultures |
US10304188B1 (en) | 2015-03-27 | 2019-05-28 | Caleb J. Kumar | Apparatus and method for automated cell analysis |
JP6725646B2 (en) | 2015-09-02 | 2020-07-22 | ベンタナ メディカル システムズ, インコーポレイテッド | Automated analysis of cell samples with a mixture of analytically distinct analyte staining patterns |
WO2017049226A1 (en) * | 2015-09-16 | 2017-03-23 | Leica Biosystems Imaging, Inc. | Automated stain finding in pathology bright-field images |
US9779499B2 (en) * | 2015-09-18 | 2017-10-03 | Definiens Ag | Grading of glandular tissue cancer by detailed image analysis of stained tissue slices |
US10783348B2 (en) * | 2015-09-22 | 2020-09-22 | Imageprovision Technology Pvt. Ltd. | Method and system for detection and classification of particles based on processing of microphotographic images |
WO2017053592A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Deep learning in label-free cell classification and machine vision extraction of particles |
WO2017085738A1 (en) * | 2015-11-21 | 2017-05-26 | Venkata Satya Suresh Attili | System and method for automated gross examination of tissues |
EP3786640B1 (en) | 2015-11-25 | 2022-08-24 | Cernostics, Inc. | Methods of detecting malignant transformation of barrett's esophagus |
CA3002902C (en) * | 2015-12-18 | 2023-05-09 | Ventana Medical Systems, Inc. | Systems and methods of unmixing images with varying acquisition properties |
TWI594207B (en) * | 2016-04-26 | 2017-08-01 | 財團法人金屬工業研究發展中心 | Cell nucleus outline capturing apparatus and method thereof |
WO2017221592A1 (en) * | 2016-06-23 | 2017-12-28 | コニカミノルタ株式会社 | Image processing device, image processing method, and image processing program |
US10453195B2 (en) * | 2016-08-19 | 2019-10-22 | Optrascan, Inc. | Method of detecting tissue area of interest in digital pathology imaging by executing computer-executable instructions stored on a non-transitory computer-readable medium |
CN109643390B (en) * | 2016-09-19 | 2023-04-18 | 赫尔实验室有限公司 | Method, system and program product for object detection using spiking neural networks |
US10430943B2 (en) | 2016-10-07 | 2019-10-01 | Sony Corporation | Automated nuclei area/number estimation for IHC image analysis |
US11048911B2 (en) * | 2016-10-27 | 2021-06-29 | Koninklijke Philips N.V. | Apparatus for determining cellular composition information in one or more tissue samples |
KR101944536B1 (en) * | 2016-12-11 | 2019-02-01 | 주식회사 딥바이오 | System and method for medical diagnosis using neural network |
US10540535B2 (en) * | 2017-03-13 | 2020-01-21 | Carl Zeiss Microscopy Gmbh | Automatically identifying regions of interest on images of biological cells |
CN106874963B (en) * | 2017-03-17 | 2018-11-02 | 南京邮电大学 | A kind of Fault Diagnosis Method for Distribution Networks and system based on big data technology |
US10535434B2 (en) | 2017-04-28 | 2020-01-14 | 4D Path Inc. | Apparatus, systems, and methods for rapid cancer detection |
US11176363B2 (en) * | 2017-09-29 | 2021-11-16 | AO Kaspersky Lab | System and method of training a classifier for determining the category of a document |
CN107832801B (en) * | 2017-11-23 | 2021-03-05 | 桂林优利特医疗电子有限公司 | Model construction method for cell image classification |
EP3762854A1 (en) * | 2018-03-07 | 2021-01-13 | Google LLC | Virtual staining for tissue slide images |
CN108896376B (en) * | 2018-03-30 | 2019-11-08 | 迈凯基因科技有限公司 | Improved HE colouring method |
US20210246643A1 (en) * | 2018-06-04 | 2021-08-12 | Binyamin Yefet SONOVANI | Systems devices and methods for detecting and diagnosing substances |
CN108921057B (en) * | 2018-06-19 | 2021-06-01 | 厦门大学 | Convolutional neural network-based prawn form measuring method, medium, terminal equipment and device |
JPWO2020012616A1 (en) * | 2018-07-12 | 2021-08-02 | ソニーグループ株式会社 | Information processing equipment, information processing methods, programs, and information processing systems |
TWI687898B (en) * | 2018-11-23 | 2020-03-11 | 宏碁股份有限公司 | Image normalization method and image processing device |
US11449987B2 (en) * | 2018-12-21 | 2022-09-20 | Wisconsin Alumni Research Foundation | Image analysis of epithelial component of histologically normal prostate biopsies predicts the presence of cancer |
EP3677185A1 (en) * | 2019-01-03 | 2020-07-08 | Koninklijke Philips N.V. | Calibrating radiological data based on cell distribution |
US10818015B2 (en) * | 2019-01-28 | 2020-10-27 | Florida Analytical Imaging Solutions, LLC. | Automatic region of interest selection in centrosome analysis |
CN109800872B (en) * | 2019-01-28 | 2022-12-16 | 电子科技大学 | Neuromorphic processor based on segmented multiplexing and parameter quantification sharing |
JP7268471B2 (en) * | 2019-05-09 | 2023-05-08 | 株式会社デンソー | Method of verification |
US20220292681A1 (en) * | 2019-08-23 | 2022-09-15 | Memorial Sloan Kettering Cancer Center | Fast whole slide tissue tiling method |
US10803586B1 (en) | 2019-09-26 | 2020-10-13 | Aiforia Technologies Oy | Image analysis in pathology |
DE102019132514B3 (en) * | 2019-11-29 | 2021-02-04 | Carl Zeiss Meditec Ag | Optical observation device and method and data processing system for determining information for distinguishing between tissue fluid cells and tissue cells |
CN111275696B (en) * | 2020-02-10 | 2023-09-15 | 腾讯医疗健康(深圳)有限公司 | Medical image processing method, image processing method and device |
US11475304B2 (en) * | 2020-05-12 | 2022-10-18 | International Business Machines Corporation | Variational gradient flow |
CN111619755B (en) * | 2020-06-09 | 2021-05-04 | 中国船舶科学研究中心 | Hull profile design method based on convolutional neural network |
US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
CN113469939B (en) * | 2021-05-26 | 2022-05-03 | 透彻影像(北京)科技有限公司 | HER-2 immunohistochemical automatic interpretation system based on characteristic curve |
WO2023049209A1 (en) * | 2021-09-22 | 2023-03-30 | Volastra Therapeutics, Inc. | Systems and methods for evaluation of mitotic events using machine-learning |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4724543A (en) * | 1985-09-10 | 1988-02-09 | Beckman Research Institute, City Of Hope | Method and apparatus for automatic digital image analysis |
US4741043B1 (en) * | 1985-11-04 | 1994-08-09 | Cell Analysis Systems Inc | Method of and apparatus for image analyses of biological specimens |
FI880818A (en) | 1987-03-18 | 1988-09-19 | Gen Electric | BILDSKAERM MED AUTOMATISK BILDJUSTERING. |
US5544650A (en) * | 1988-04-08 | 1996-08-13 | Neuromedical Systems, Inc. | Automated specimen classification system and method |
US5235522A (en) * | 1990-10-10 | 1993-08-10 | Cell Analysis Systems, Inc. | Method and apparatus for automated analysis of biological specimens |
US5546323A (en) * | 1990-10-10 | 1996-08-13 | Cell Analysis Systems, Inc. | Methods and apparatus for measuring tissue section thickness |
US5427910A (en) | 1992-12-09 | 1995-06-27 | Compucyte Corporation | Method of cytogenetic analysis |
US6418236B1 (en) * | 1999-06-24 | 2002-07-09 | Chromavision Medical Systems, Inc. | Histological reconstruction and automated image analysis |
US6151405A (en) * | 1996-11-27 | 2000-11-21 | Chromavision Medical Systems, Inc. | System and method for cellular specimen grading |
US6215892B1 (en) * | 1995-11-30 | 2001-04-10 | Chromavision Medical Systems, Inc. | Method and apparatus for automated image analysis of biological specimens |
US6718053B1 (en) * | 1996-11-27 | 2004-04-06 | Chromavision Medical Systems, Inc. | Method and apparatus for automated image analysis of biological specimens |
US6330349B1 (en) * | 1995-11-30 | 2001-12-11 | Chromavision Medical Systems, Inc. | Automated method for image analysis of residual protein |
US6396941B1 (en) * | 1996-08-23 | 2002-05-28 | Bacus Research Laboratories, Inc. | Method and apparatus for internet, intranet, and local viewing of virtual microscope slides |
US6272235B1 (en) * | 1997-03-03 | 2001-08-07 | Bacus Research Laboratories, Inc. | Method and apparatus for creating a virtual microscope slide |
US6404906B2 (en) * | 1997-03-03 | 2002-06-11 | Bacus Research Laboratories,Inc. | Method and apparatus for acquiring and reconstructing magnified specimen images from a computer-controlled microscope |
US6009342A (en) * | 1997-02-28 | 1999-12-28 | The Regents Of The University Of California | Imaging method for the grading of tumors |
US6911315B2 (en) * | 1997-11-24 | 2005-06-28 | David L. Rimm | Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood |
JP2002503814A (en) * | 1998-02-12 | 2002-02-05 | イムニベスト・コーポレイション | Methods and reagents for rapid and efficient isolation of circulating cancer cells |
US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
DE19935671A1 (en) * | 1998-08-06 | 2000-02-10 | Wella Ag | Sheet with anti-slip surface comprises bonded anti-slip and higher-tensile plastics, suitable for covering objects including shampoo bottles to which it confers temperate, value-enhancing feel |
JP3913388B2 (en) | 1999-02-01 | 2007-05-09 | 三洋電機株式会社 | Solid-state imaging device |
AU762085B2 (en) * | 1999-04-13 | 2003-06-19 | Chromavision Medical Systems, Inc. | Histological reconstruction and automated image analysis |
US6674896B1 (en) * | 1999-07-13 | 2004-01-06 | Chromavision Medical Systems, Inc. | Device for applying accurate color thresholds in real time |
EP1218849A1 (en) * | 1999-07-13 | 2002-07-03 | Chromavision Medical Systems, Inc. | Apparatus for counting color transitions and areas in real time camera images |
WO2001011547A1 (en) * | 1999-08-04 | 2001-02-15 | Chromavision Medical Systems, Inc. | Method and apparatus for applying color thresholds in light microscopy |
AU7494900A (en) | 1999-09-17 | 2001-04-17 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Signal counting for in situ hybridization |
WO2001042796A1 (en) | 1999-12-13 | 2001-06-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health | High-throughput tissue microarray technology and applications |
US20040115692A1 (en) * | 2000-04-03 | 2004-06-17 | Cytyc Corporation | Methods, compositions and apparatuses for detecting a target in a preservative solution |
US6711283B1 (en) * | 2000-05-03 | 2004-03-23 | Aperio Technologies, Inc. | Fully automatic rapid microscope slide scanner |
US7518652B2 (en) * | 2000-05-03 | 2009-04-14 | Aperio Technologies, Inc. | Method and apparatus for pre-focus in a linear array based slide scanner |
US7738688B2 (en) * | 2000-05-03 | 2010-06-15 | Aperio Technologies, Inc. | System and method for viewing virtual slides |
US6518554B1 (en) * | 2000-05-24 | 2003-02-11 | Chromavision Medical Systems, Inc. | Reverse focusing methods and systems |
AU2002211835A1 (en) * | 2000-09-29 | 2002-04-08 | Clinomics Laboratories, Inc. | Oncology tissue microarrays |
US6998234B2 (en) * | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
US7171030B2 (en) | 2000-11-30 | 2007-01-30 | University Of Medicine & Denistry Of New Jersey | Systems for analyzing microtissue arrays |
US20030215936A1 (en) * | 2000-12-13 | 2003-11-20 | Olli Kallioniemi | High-throughput tissue microarray technology and applications |
US20040085443A1 (en) * | 2000-12-13 | 2004-05-06 | Kallioniemi Olli P | Method and system for processing regions of interest for objects comprising biological material |
US20020168657A1 (en) * | 2001-02-02 | 2002-11-14 | Chen Lan Bo | Rare event detection system |
US20030068626A1 (en) * | 2001-02-09 | 2003-04-10 | Pintex Pharmaceuticals, Inc. | Pin1 as a marker for abnormal cell growth |
AU2002255525B2 (en) * | 2001-02-09 | 2007-01-04 | Pintex Pharmaceuticals, Inc. | Pin1 as a marker for prostate cancer |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
US6935626B2 (en) | 2001-07-25 | 2005-08-30 | Orscheln Products Llc | Spring assembly |
US7332290B2 (en) * | 2001-08-02 | 2008-02-19 | The Regents Of The University Of Michigan | Dectection of AMACR cancer markers in urine |
EP1427810B9 (en) * | 2001-08-21 | 2012-04-25 | Ventana Medical Systems, Inc. | Method and quantification assay for determining c-kit/scf/pakt status |
US7863012B2 (en) * | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
WO2003025543A2 (en) * | 2001-09-21 | 2003-03-27 | The Regents Of The University Of California | Methods of cytodiagnostic staging of neoplasia and squamous cell carcinoma |
US6697509B2 (en) * | 2001-10-04 | 2004-02-24 | Chromavision Medical Systems, Inc. | Method and apparatus for scoring the uptake of markers in cells |
TWI227285B (en) * | 2001-10-15 | 2005-02-01 | Univ Southern California | Methods of and apparatus for producing a three-dimensional structure |
US7383134B2 (en) * | 2002-01-15 | 2008-06-03 | Piper James R | Method and/or system for analyzing biological samples using a computer system |
US20030165263A1 (en) * | 2002-02-19 | 2003-09-04 | Hamer Michael J. | Histological assessment |
CA2436043C (en) * | 2002-02-22 | 2006-01-10 | Bacus Research Laboratories, Inc. | Focusable virtual microscopy apparatus and method |
US20040180889A1 (en) * | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US20040176372A1 (en) * | 2002-03-01 | 2004-09-09 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US7272252B2 (en) * | 2002-06-12 | 2007-09-18 | Clarient, Inc. | Automated system for combining bright field and fluorescent microscopy |
US20050037406A1 (en) * | 2002-06-12 | 2005-02-17 | De La Torre-Bueno Jose | Methods and apparatus for analysis of a biological specimen |
US6800249B2 (en) * | 2002-06-14 | 2004-10-05 | Chromavision Medical Systems, Inc. | Automated slide staining apparatus |
CA2492071A1 (en) | 2002-06-18 | 2003-12-24 | Lifespan Biosciences, Inc. | Computerized image capture of structures of interest within a tissue sample |
US7188092B2 (en) * | 2002-07-12 | 2007-03-06 | Chroma Energy, Inc. | Pattern recognition template application applied to oil exploration and production |
US20040214872A1 (en) * | 2002-09-26 | 2004-10-28 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US7200252B2 (en) * | 2002-10-28 | 2007-04-03 | Ventana Medical Systems, Inc. | Color space transformations for use in identifying objects of interest in biological specimens |
CA2503417A1 (en) * | 2002-10-31 | 2004-05-21 | E. I. Du Pont De Nemours And Company | Color selection method |
AU2003290988A1 (en) * | 2002-11-14 | 2004-06-15 | Pintex Pharmaceuticals, Inc. | Levels of pin1 in normal and cancerous tissue |
WO2004077021A2 (en) * | 2003-02-27 | 2004-09-10 | Lesko Stephen A | Standardized evaluation of therapeutic efficacy based on cellular biomarkers |
US7257268B2 (en) * | 2003-02-28 | 2007-08-14 | Aperio Technologies, Inc. | Systems and methods for image pattern recognition |
US7116440B2 (en) * | 2003-02-28 | 2006-10-03 | Aperio Technologies, Inc. | Image processing and analysis framework |
US20040176277A1 (en) * | 2003-03-03 | 2004-09-09 | Pintex Pharmaceuticals, Inc. | Methods of treating Pin1 associated disorders |
US7186522B2 (en) * | 2003-03-31 | 2007-03-06 | Cytyc Corporation | Papanicolau staining process |
US20040202357A1 (en) * | 2003-04-11 | 2004-10-14 | Perz Cynthia B. | Silhouette image acquisition |
US20050004024A1 (en) * | 2003-04-17 | 2005-01-06 | Pintex Pharmaceuticals, Inc. | Methods of treating Pin1 associated disorders by covalent modification of active site residues |
US7282180B2 (en) * | 2003-07-02 | 2007-10-16 | Immunivest Corporation | Devices and methods to image objects |
US20050136549A1 (en) * | 2003-10-30 | 2005-06-23 | Bioimagene, Inc. | Method and system for automatically determining diagnostic saliency of digital images |
US20050136509A1 (en) * | 2003-09-10 | 2005-06-23 | Bioimagene, Inc. | Method and system for quantitatively analyzing biological samples |
US8068988B2 (en) | 2003-09-08 | 2011-11-29 | Ventana Medical Systems, Inc. | Method for automated processing of digital images of tissue micro-arrays (TMA) |
US20050069900A1 (en) * | 2003-09-25 | 2005-03-31 | Cytyc Corporation | Analyte sample detection |
US7803624B2 (en) * | 2003-09-30 | 2010-09-28 | Cytyc Corporation | Automated cytological sample classification |
WO2005076197A2 (en) | 2004-01-31 | 2005-08-18 | Bioimagene, Inc. | Method and system for morphology based mitosis identification and classification of digital images |
-
2004
- 2004-09-10 US US10/938,314 patent/US20050136509A1/en not_active Abandoned
- 2004-09-10 WO PCT/US2004/029766 patent/WO2005027015A2/en active Application Filing
-
2005
- 2005-01-31 US US11/048,541 patent/US7979212B2/en active Active
- 2005-03-27 US US11/091,614 patent/US7941275B2/en active Active
-
2011
- 2011-04-04 US US13/079,719 patent/US8515683B2/en active Active
Non-Patent Citations (1)
Title |
---|
COMANICIU D ET AL: "Image-guided decision support system for pathology" MACHINE VISION AND APPLICATIONS, SPRINGER VERLAG, DE, vol. 11, no. 4, 1999, pages 213-224, XP002314404 ISSN: 0932-8092 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8655037B2 (en) | 2007-05-14 | 2014-02-18 | Historx, Inc. | Compartment segregation by pixel characterization using image data clustering |
US8417015B2 (en) | 2007-08-06 | 2013-04-09 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
GB2485883A (en) * | 2010-11-26 | 2012-05-30 | Siemens Medical Solutions | Retrieval and reviewing of medical image processing |
US8638997B2 (en) | 2010-11-26 | 2014-01-28 | Siemens Medical Solutions Usa, Inc. | Methods and systems for medical image processing, retrieval, and reviewing |
WO2017051190A1 (en) * | 2015-09-23 | 2017-03-30 | Pathxl Limited | Method and apparatus for tissue recognition |
US10565706B2 (en) | 2015-09-23 | 2020-02-18 | Koninklijke Philips N.V. | Method and apparatus for tissue recognition |
Also Published As
Publication number | Publication date |
---|---|
US8515683B2 (en) | 2013-08-20 |
US20050136509A1 (en) | 2005-06-23 |
WO2005027015A3 (en) | 2005-06-16 |
US7979212B2 (en) | 2011-07-12 |
US7941275B2 (en) | 2011-05-10 |
US20110311123A1 (en) | 2011-12-22 |
US20060014238A1 (en) | 2006-01-19 |
US20050266395A1 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050136509A1 (en) | Method and system for quantitatively analyzing biological samples | |
JP6816196B2 (en) | Systems and methods for comprehensive multi-assay histology analysis | |
US8068988B2 (en) | Method for automated processing of digital images of tissue micro-arrays (TMA) | |
US11195279B1 (en) | Systems and methods for training a statistical model to predict tissue characteristics for a pathology image | |
US20220375101A1 (en) | Foreground segmentation and nucleus ranking for scoring dual ish images | |
Bueno et al. | New trends of emerging technologies in digital pathology | |
US20050265588A1 (en) | Method and system for digital image based flourescent in situ hybridization (FISH) analysis | |
US7760927B2 (en) | Method and system for digital image based tissue independent simultaneous nucleus cytoplasm and membrane quantitation | |
JP7092503B2 (en) | Systems and methods for co-expression analysis | |
US6246785B1 (en) | Automated, microscope-assisted examination process of tissue or bodily fluid samples | |
Rangan et al. | Quantification of renal pathology by image analysis (Methods in Renal Research) | |
EP2810213B1 (en) | System for detecting genes in tissue samples | |
JP2022534156A (en) | Artificial intelligence processing system and automated pre-diagnosis workflow for digital pathology | |
EP3251087B1 (en) | Dot detection, color classification of dots and counting of color classified dots | |
JP7197584B2 (en) | Methods for storing and retrieving digital pathology analysis results | |
US20050136549A1 (en) | Method and system for automatically determining diagnostic saliency of digital images | |
JP2017224327A (en) | Method and system for analyzing biological specimen by spectral imaging | |
JP2022534157A (en) | Computer-assisted review of tumors on histological images and postoperative tumor margin assessment | |
US20060109343A1 (en) | Image displaying system, image providing apparatus, image displaying apparatus, and computer readable recording medium | |
WO2007024264A2 (en) | Method and system for digital image based tissue independent simultaneous nucleus, cytoplasm and membrane quantitation | |
US11436727B2 (en) | Systems and methods to process electronic images to provide image-based cell group targeting | |
Liu et al. | Reproducible, high-dimensional imaging in archival human tissue by multiplexed ion beam imaging by time-of-flight (MIBI-TOF) | |
US11727674B2 (en) | Systems and methods for generating histology image training datasets for machine learning models | |
WO2005076216A2 (en) | Method and system for automaticed digital image based flourescent in situ hybridization (fish) analysis | |
Saidi et al. | Technology insight: will systems pathology replace the pathologist? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |